The Tape Can't Price Lumentum. It Isn't Pricing POET Either

Monday was supposed to be the bounce. The Dow was up close to 1%, the S&P 500 was flat, and the Nasdaq was barely red. The chip & optics board said otherwise, and the AI stocks selloff was right back on. Marvell Marvell Technology (MRVL) down 12%. Lumentum $LITE down 18%. Applied Optoelectronics $AAOI down 10%, Intel Intel (INTC) and CoreWeave $CRWV down 8%, AMD Advanced Micro Devices (AMD) down 6%, POET Technologies POET Technologies (POET) down 8%. That isn't a crash. That's a rotation, and the money leaving AI hardware isn't waiting around to hear the bull case. Here's what moved it, and what it means for a stock that now trades about 40 cents above its own net cash.

The Marvell Lumentum deal: a 24% premium that became a 25% haircut

Marvell confirmed it Monday morning. $115 billion of enterprise value, all stock, 4.5 Marvell shares for every Lumentum share. Marvell said the ratio was worth $1,132 a share and a 23.9% premium at Oct. 28 prices. Closing isn't expected until the first half of 2028, regulators in both Washington and Beijing get a say, and Marvell holders end up diluted by a third.

The market's verdict was to sell both. By early afternoon Marvell had lost more than 30% over three sessions, a slide Benzinga was already calling the worst since September 2001. And here's the mechanic LITE holders are living with: the offer isn't a number, it's a ratio. At $173 for Marvell, 4.5 shares are worth about $779 per Lumentum share. LITE traded at $689. That's 13% below the live offer, and by our math roughly 25% below where it sat before Bloomberg leaked the talks. A target gets a 24% premium bid & ends up a quarter cheaper. Lumentum's scarcity premium walked out the door the moment it agreed to take paper. Coherent $COHR, the read-through name among AI optics stocks, caught an early bid, then gave it all back.

That's the tell for everything that follows. A market that can't price Lumentum with a signed $115 billion offer on the table isn't pricing businesses right now. It's pricing deal currency, dilution and time. For photonics stocks of every size, that's the regime.

Oracle paid for borrowing. Google didn't.

The Oracle stock offering landed the same morning. Oracle Oracle (ORCL) came to market for $20 billion, half investment-grade bonds and half stock, to fund AI capex and dividends, and the stock fell about 5%. Alphabet $GOOG lined up a 6 billion euro bond sale the same day and rose. Microsoft $MSFT sold $25 billion of notes last week without drama. Same purpose, opposite reactions, and the difference is leverage. Investors are sorting the buildout by balance sheet now, not by GPU count. CoreWeave, the most leveraged way to own it, fell 8%. We've called it the canary before. It's still singing.

Friday's semiconductor selloff never ended

The backdrop was already fragile. Intel lost more than 28% Friday after a beat that came with weak PC numbers, AMD gave up about a tenth of its value, and the Philadelphia Semiconductor Index dropped roughly 6%. The iShares Semiconductor ETF ended the week 29% off its high, a bear market by any definition, and roughly $5 trillion came out of AI stocks in three weeks. On Monday Bank of America's economists called a sustained AI correction one of the larger risks to the U.S. and global economy, per Yahoo Finance.

The earnings didn't help. Alphabet fell 13% last week on a miss, with AI eating into search monetization, and Amazon missed on both lines. Then Anthropic's amended S-1 showed $33.2 billion of revenue through nine months next to enormous spending commitments. The question from every direction is the same one: where's the return. Our read is that investors now want cash flow and a clear payback before they'll pay premium prices for future AI growth. That's why the selling runs across chips, cloud infrastructure & optics instead of stopping at one.

Oil fell 7.5% and nobody cared

Here's the plot twist. In October we argued oil and bonds were running AI stocks. Monday crude fell 7.5% to about $96 on reports the U.S. and Iran are looking for a diplomatic way out of the war, Brent slipped toward $105, and the 10-year eased to 4.89%. The AI complex sold off anyway. So this leg isn't about Hormuz. It's about dilution and capex returns, and no ceasefire fixes that. Rates didn't help either, with fed funds futures pricing a 76% chance of a December hike.

Which brings us to POET stock at $4.80

POET fell 7.8% to $4.795 Monday, right in line with the group, on the morning it announced a new CFO hired out of Silicon Labs. The tape read the release premarket as positive, but for the last few hours it’s reading the sector.

Now the arithmetic, and only the arithmetic. At $4.795, POET's 173 million basic shares are worth about $830 million. The company reported $796.3 million of cash and short-term investments at June 30, with no debt ahead of the common. Take out liabilities and net cash runs about $4.40 a share. That leaves about 40 cents a share, roughly $68 million, for everything else: 49 patents and 37 applications, the Lumilens $50 million order inside a framework that can reach $500 million, a company of 150-plus people, and six straight quarters of sequential revenue growth through Q2. Two weeks ago we put 98 cents a share on the business at $5.38. Monday it's 40 cents. The business didn't lose 60% of itself in two weeks. The price did.

We walked through the hurdles side of this ledger in October. The cash side gets re-based on Nov. 16, when the Q3 release lands at 7:00 a.m. ET with no call. Burn and capex come out of that number, so both halves of the ledger move that morning. We're not putting a price target on it. We don't do that here. Build your own number.

Irrational cuts both ways

Start with the up-leg, because nobody does. POET stock ran from $3.81 to $20.81 inside twelve months on about $1 million of half-year sales. Nobody wrote a piece calling that irrational. They called it a re-rating. The machinery that did it, sector beta, dealer hedging, retail flow, is the same machinery now running in reverse. The patents, the order and the headcount all moved one direction between those two prints. Only the price went both ways.

Second, cash gets read by mood. In a rising tape $796 million is a war chest. In a selloff it's runway the company will burn. Biotech investors lived through this in 2022, when a long list of companies traded below their own cash. There's no law that stops the business line at zero.

Third, for a pre-revenue company the price is a fundamental. POET has 78.7 million warrants outstanding at a $4.39 average strike. At $4.80 nobody exercises for 41 cents of intrinsic value when the option is worth more alive, so that funding channel is shut until the stock moves. The stock stops working as deal currency. And yes, customers look at market caps.

Now the flip side, and Monday proved it. POET doesn't need the market. It's equity-funded with nothing ahead of the common, the exact trait the tape rewarded in Google and punished in Oracle on the same day. A company with $796 million against roughly $15 million a quarter of operating burn can out-wait an irrational tape. A leveraged one can't. Funded, not leveraged, isn't a slogan this week. It's the only thing the market paid for.

And the mirror. If the tape can't price Lumentum with $115 billion in writing, it isn't pricing POET's IP either. That's noise in both directions, & you can likely guess which way the noise runs when the group is down 8% to 18% in a day. Nov. 16 is the first date the business gets to answer with a number instead of a print.

What we're watching

We're watching whether LITE closes the gap to the 4.5-share value or Marvell falls to meet it; a gap that widens says the market thinks the deal is in trouble. We're watching whether Oracle's $10 billion of stock clears without another leg down, since that sets the price of equity for every leveraged AI name behind it. And we're watching the Sept. 30 cash number on Nov. 16, the half of POET's ledger about to move, and the half the market has been treating as the whole thing.

Subscribe to StockAlpha.ai for the next one.